Glycemic control and high-density lipoprotein characteristics in adolescents with type 1 diabetes

Patricia Medina-Bravo1, Aída Medina-Urrutia, Juan Gabriel Juárez-Rojas

  • 1Department of Endocrinology, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico.

Pediatric Diabetes
|October 13, 2012
PubMed

Insights

Poor glycemic control in adolescents with type 1 diabetes is linked to altered high-density lipoprotein (HDL) subclasses and composition. However, HDL

Area of Science:

  • Cardiovascular Health
  • Metabolic Disorders
  • Pediatric Endocrinology

Background:

  • High-density lipoprotein (HDL) function, not just levels, is increasingly recognized for coronary heart disease prediction.
  • Limited data exists on HDL subclasses in youth with type 1 diabetes.

Purpose of the Study:

  • To investigate the relationship between glycemic control and HDL subclasses, composition, and function in adolescents with type 1 diabetes.

Main Methods:

  • Cross-sectional study of 52 adolescents with type 1 diabetes and 43 controls (ages 12-16).
  • Participants categorized by glycemic control: fair (HbA1c < 9.6%) and poor (HbA1c ≥ 9.6%).
  • Assessed HDL subclasses, composition, cholesterol efflux capacity, and soluble adhesion molecules.

Main Results:

  • Poor glycemic control group showed reduced HDL2b subclass, increased triglyceride-rich HDL, and depleted cholesteryl ester HDL particles compared to controls.
  • Despite HDL alterations, cholesterol efflux capacity was similar across all groups.
  • Elevated intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 were observed in the poor control group.

Conclusions:

  • Poor glycemic control in adolescents with type 1 diabetes is associated with abnormal HDL subclasses and lipid composition.
  • HDL's cholesterol efflux capacity remains preserved in adolescents with type 1 diabetes despite glycemic control status.
Abstract

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...